If you’ve been exploring functional mushrooms, you’ve likely encountered the term beta-glucans. These naturally occurring polysaccharides are widely cited as the primary reason mushrooms offer meaningful health benefits. But beyond immune support, there’s a growing body of research exploring a more specific question: can beta-glucans from functional mushrooms help manage cholesterol levels?
The answer is nuanced, and the science is more promising than most supplement marketing lets on. Here’s what the research actually shows.
What Are Beta-Glucans?
Beta-glucans are long-chain polysaccharides found in the cell walls of fungi, oats, barley, and certain yeasts. In mushrooms specifically, they appear primarily as (1,3)/(1,6)-beta-D-glucans, a molecular structure that gives them their distinctive biological activity.
These compounds are classified as soluble dietary fiber, and it’s this fiber-like quality that underpins much of their proposed cholesterol-lowering effect. A comprehensive review published in 2018 outlined multiple mechanisms by which beta-glucans may influence lipid metabolism, including modulation of bile acid reabsorption and changes to gut microbiota composition.[1]
To understand beta-glucans in greater depth, including their structure and broader health roles, see our overview: Beta-Glucans: The Active Compound That Makes Mushrooms So Powerful.
The Cholesterol Connection: How It Works
Beta-glucans are thought to influence cholesterol through several interlocking pathways:
Bile Acid Sequestration
Bile acids are produced in the liver using cholesterol as a raw material. Normally, the gut reabsorbs these acids and recycles them. Beta-glucans, acting as viscous soluble fiber, can bind to bile acids in the intestine and prevent their reabsorption. The liver then pulls more cholesterol from the blood to produce fresh bile acids, which effectively lowers circulating LDL cholesterol.
Short-Chain Fatty Acid Production
When gut bacteria ferment beta-glucans, they produce short-chain fatty acids (SCFAs) such as propionate. Propionate has been shown in laboratory studies to inhibit hepatic cholesterol synthesis, adding another potential layer to the lipid-lowering effect.
Gut Microbiome Modulation
Research published in 2021 found that consumption of a β-D-glucan-enriched extract from shiitake mushrooms altered the intestinal microbiota in ways that may support improved lipid profiles.[2] This gut-heart axis is an active area of investigation, and while mushroom-derived beta-glucans differ structurally from oat beta-glucans, early findings are encouraging.
Functional Mushrooms With the Most Relevant Research
Oyster Mushrooms (Pleurotus ostreatus)
Oyster mushrooms are among the most studied functional mushrooms for cardiovascular outcomes. A systematic review examining the effects of oyster mushroom consumption on cardiometabolic parameters found meaningful reductions in total cholesterol and LDL across multiple studies, though effect sizes varied depending on the form consumed (whole food vs. extract) and the population studied.[3] The authors noted that oyster mushrooms contain both beta-glucans and lovastatin, a naturally occurring statin compound, which may contribute to their observed lipid effects.
Reishi (Ganoderma lucidum)
Reishi mushrooms contain a distinct class of beta-glucans alongside triterpenes, both of which may play a role in cardiovascular health. A 2021 review examining beta-glucans as a potential therapeutic for cardiovascular disease highlighted Ganoderma species among the fungi with the most documented lipid-modifying properties.[4] Reishi’s polysaccharide fraction has been explored in animal and in vitro models with results suggesting reduced LDL oxidation and improved HDL-to-LDL ratios, though human clinical trials remain limited.
Shiitake (Lentinula edodes)
Shiitake mushrooms contain lentinan, a specific beta-glucan, as well as eritadenine, a compound thought to inhibit an enzyme involved in cholesterol metabolism. Early studies in animal models showed substantial reductions in plasma cholesterol, and some small human trials have shown similar directional effects, though large-scale randomized controlled trials are still needed.
Chaga (Inonotus obliquus)
Chaga is rich in beta-glucans and has significant antioxidant activity via betulinic acid and melanin pigments. While most cardiovascular research on Chaga focuses on its anti-inflammatory potential, its beta-glucan content places it within the broader functional mushroom category of interest for lipid management.
What the Research Can and Cannot Yet Confirm
A 2021 review on beta-glucan’s metabolic and immunomodulatory properties emphasized that the field is still developing: effects appear dose-dependent, structure-dependent (molecular weight matters), and influenced heavily by individual gut microbiome composition.[5]
Key caveats worth noting:
- Most high-quality evidence for beta-glucans and cholesterol comes from oat and barley studies, not mushrooms specifically
- Mushroom beta-glucans have a different (1,3)/(1,6) branching structure compared to the (1,3)/(1,4) found in oats, which may mean different potency or mechanisms
- Many mushroom studies use extracts at concentrations that are difficult to achieve through food alone
- Human clinical trials specifically on mushroom-derived beta-glucans and cholesterol are still limited in number and sample size
None of this means the research is weak: it means it’s early. The mechanistic pathways are well-understood, the animal and in vitro data are promising, and human trials are underway.
Practical Considerations for Supplementing
If you’re exploring functional mushrooms as part of a broader cardiovascular wellness strategy, here’s what to look for in a supplement:
- Beta-glucan content listed on the label: Reputable products disclose the percentage of active beta-glucans. A product listing only “mushroom powder” without beta-glucan content provides no assurance of potency.
- Fruiting body vs. mycelium: Beta-glucan concentrations are generally higher in fruiting bodies. Mycelium grown on grain substrate can contain significant starch from the grain, diluting the active compound.
- Certificate of Analysis (COA): Third-party testing confirms that the stated beta-glucan content matches what’s in the product.
- Form matters: Some research suggests that beta-glucan bioavailability may differ between whole food forms and isolated extracts.
The Bottom Line
Beta-glucans represent one of the most scientifically grounded mechanisms through which functional mushrooms may support cardiovascular health. While the strongest clinical evidence for beta-glucans and cholesterol reduction comes from cereal grains, the structural properties of mushroom-derived beta-glucans and their effects on bile acids, gut bacteria, and hepatic cholesterol synthesis suggest a real and meaningful role in lipid management.
For those already working with a healthcare provider on cholesterol management, functional mushrooms with high beta-glucan content: oyster, reishi, shiitake, and chaga among them: may be a worthwhile addition to a broader lifestyle approach. They’re not a replacement for medication or dietary intervention, but the emerging evidence suggests they’re more than just marketing.
References
- [1] Sima P, et al. β-glucans and cholesterol (Review). Int J Mol Med. 2018.
- [2] Morales D, et al. Modulation of human intestinal microbiota by consumption of a β-D-glucan-enriched extract from Lentinula edodes. Eur J Nutr. 2021.
- [3] Dicks L, et al. Effect of oyster mushrooms (Pleurotus ostreatus) on cardiometabolic parameters: A systematic review. Nutrients. 2020.
- [4] Wouk J, et al. β-Glucans as a panacea for a healthy heart? Their roles in preventing and treating cardiovascular diseases. Int J Biol Macromol. 2021.
- [5] Murphy EJ, et al. β-Glucan metabolic and immunomodulatory properties and potential for clinical application. J Fungi. 2020.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement.
